Clinical Trials /

Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Adult Patients With Ph+ ALL

NCT04554459

Description:

This is a phase II interventional trial to evaluate the efficacy of ponatinib plus reduced-intensity chemotherapy in the first-line treatment of adult patients with Ph+ acute lymphoblastic leukemia. This combination has the potential to improve the depth of molecular responses after the induction phase of treatment. Patients who achieve a complete molecular response (CMR) at week 11 will not be directed to alloSCT and will receive consolidation chemotherapy combined with ponatinib, followed by 24 months of ponatinib maintenance. The aim is to spare individuals with a low probability of relapse from overtreatment with more intensive and toxic transplant procedure.

Related Conditions:
  • B-Cell Acute Lymphoblastic Leukemia
Recruiting Status:

Not yet recruiting

Phase:

Phase 2

Trial Eligibility

Document

Title

  • Brief Title: Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Adult Patients With Ph+ ALL
  • Official Title: Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Adult Patients With Ph-positive Acute Lymphoblastic Leukemia

Clinical Trial IDs

  • ORG STUDY ID: Pona-CELL
  • NCT ID: NCT04554459

Conditions

  • Acute Lymphoblastic Leukemia, Adult
  • Ph+ ALL
  • Newly Diagnosed

Interventions

DrugSynonymsArms
Ponatinib 15 MG Oral TabletIclusig, AP24534, L01XE24ponatinib plus reduced-intensity chemotherapy

Purpose

This is a phase II interventional trial to evaluate the efficacy of ponatinib plus reduced-intensity chemotherapy in the first-line treatment of adult patients with Ph+ acute lymphoblastic leukemia. This combination has the potential to improve the depth of molecular responses after the induction phase of treatment. Patients who achieve a complete molecular response (CMR) at week 11 will not be directed to alloSCT and will receive consolidation chemotherapy combined with ponatinib, followed by 24 months of ponatinib maintenance. The aim is to spare individuals with a low probability of relapse from overtreatment with more intensive and toxic transplant procedure.

Detailed Description

      Primary Objective:

      To evaluate the percentage of complete molecular responses (CMR) after two cycles of
      remission induction therapy composed of two cycles of chemotherapy plus ponatinib. CMR is
      defined as BCR-ABL1 below the Limit of Quantification by Droplet Digital Polymerase Chain
      Reaction (ddPCR).

      Outline:

      Pre-phase:

      dexamethasone 10 mg/m2 PO (day -5 till -1), cyclophosphamide IV 200 mg/m2 (day -3 till -1),
      methotrexate 15 mg IT.

      Induction I:

      ponatinib 30 mg/day PO once daily (QD) continuously since day 1, rituximab 375 mg/m2 IV (day
      1), dexamethasone 10 mg/m2 PO (day 1-2, 8-11), vincristine 2 mg IV (day 1, 8, 15),
      Granulocyte-Colony Stimulating Factor (G-CSF) until recovery.

      Induction II:

      ponatinib 30 mg/day PO QD continuously, rituximab 375 mg/m2 IV (day 23), cyclophosphamide
      1000 mg/m2 IV (day 24), cytarabine 75 mg/m2 IV (day 26-29, 33-36), Granulocyte StimuG-CSF
      until recovery, methotrexate 15 mg IT (day 26, 33) methotrexate 15 mg + cytarabine 40 mg +
      dexamethasone 4 mg IT (day 40). Week 11: Primary endpoint assessment.

      Consolidation I (week 12):

      ponatinib 30 mg/day PO QD continuously, rituximab 375 mg/m2 IV (day 1), dexamethasone 10
      mg/m2 PO (day 1-4), vindesine 3 mg/m2 IV (day 2), methotrexate 1.5 g/m2 IV (day 2),
      cytarabine 2x 2 g/m2 IV (day 5), G-CSF until recovery, methotrexate 15 mg + cytarabine 40 mg
      + dexamethasone 4 mg IT (day 8). Patients in complete molecular response at week 11 will be
      treated with 5 additional blocks of chemotherapy followed by maintenance therapy; patients
      with molecular failure at week 11 will end the study and be directed to alloSCT.

      Consolidation II (week 18):

      ponatinib 15 mg/day PO QD continuously, rituximab 375 mg/m2 IV (day 1), cyclophosphamide 500
      mg/m2 IV (day 2,3), etoposide (VP-16) 75 mg/m2 IV (day 2,3), methotrexate 15 mg + cytarabine
      40 mg + dexamethasone 4 mg IT (day 1).

      Consolidation III+V (weeks 24 and 36):

      ponatinib 15 mg/day PO QD continuously, rituximab 375 mg/m2 IV (day 1), methotrexate 1.5 g/m2
      IV (day 2), vincristine 1 mg IV (day 2), 6-mercaptopurine 60 mg/m2 PO (day 2-8), methotrexate
      15 mg + cytarabine 40 mg + dexamethasone 4 mg IT at day 1.

      Consolidation IV+VI (weeks 30+40):

      ponatinib 15 mg/day PO QD continuously, rituximab 375 mg/m2 IV (day 1), dexamethasone 10
      mg/m2 PO (day 1-4), cytarabine 1.5 g/m2 IV (day 1+3+5), methotrexate 15 mg + cytarabine 40 mg
      + dexamethasone 4 mg IT (day 1). Maintenance: ponatinib 15 mg/day PO QD continuously 24
      months. (Doses of IV methotrexate and cytarabine are reduced in patients >55 years.)
    

Trial Arms

NameTypeDescriptionInterventions
ponatinib plus reduced-intensity chemotherapyExperimentalponatinib plus reduced-intensity chemotherapy in first-line treatment of Adult Ph+ ALL
  • Ponatinib 15 MG Oral Tablet

Eligibility Criteria

        Inclusion Criteria:

          -  Patients with newly diagnosed, previously untreated, Ph-positive [either t(9;22)
             and/or BCR-ABL positive] B-precursor acute lymphoblastic leukemia;

          -  Age 18-65 years;

          -  Eligible to intensive chemotherapy, due to general health status;

          -  ECOG (Eastern Cooperative Oncology Group) performance status ≤2;

          -  Absence of significant liver disease, as defined by the following criteria: total
             serum bilirubin ≤1.5 x upper limit of normal (ULN), unless due to Gilbert's syndrome,
             alanine aminotransferase (ALT) ≤2.5 × ULN or ≤5 x ULN if leukemic involvement of the
             liver is present, and aspartate aminotransferase (AST) ≤2.5 × ULN or ≤5 x ULN if
             leukemic involvement of the liver is present;

          -  Adequate pancreatic function as defined by serum amylase and lipase ≤1.5 × ULN;

          -  Diagnostic sample of bone marrow (or peripheral blood with >50% of blasts) available
             for central MRD assessment;

          -  Subject has provided written informed consent prior to any screening procedure.

        Exclusion Criteria:

          -  Lymphoid blast crisis of chronic myelocytic leukemia (CML);

          -  Active serious infection not controlled by oral or intravenous antibiotics;

          -  Active known hepatitis B virus (HBV) or hepatitis C virus (HCV) or positive HIV
             serology;

          -  History of acute pancreatitis within 1 year of study or history of chronic
             pancreatitis;

          -  Uncontrolled hypertriglyceridemia (triglycerides > 5.1 µmol/L);

          -  Clinically significant, uncontrolled or active cardiovascular disease, specifically
             including, but not restricted to: any history of myocardial infarction, stroke, or
             revascularization; unstable angina or transient ischemic attack within 6 months prior
             to enrolment; congestive heart failure within 6 months prior to enrolment or left
             ventricular ejection fraction (LVEF) less than lower limit of normal per local
             institutional standards; history of clinically significant (as determined by the
             treating physician) atrial arrhythmia; any history of ventricular arrhythmia; any
             history of venous thromboembolism including deep venous thrombosis or pulmonary
             embolism;

          -  Uncontrolled hypertension (diastolic blood pressure >90 mmHg; systolic >140 mmHg).
             Patients with hypertension should be under treatment on study entry to effect blood
             pressure control;

          -  Creatinine levels > 160 µmol/L or estimated creatinine clearance of < 50 mL/min;

          -  GI disease and/or major GI surgery that may significantly alter the absorption of
             study drug

          -  Hypersensitivity to the active substance or to any of the excipients, especially
             galactose intolerance.

          -  Taking any medications or herbal supplements that are known to be strong inhibitors of
             CYP3A4 within at least 14 days before the first dose of ponatinib;

          -  Female patients who are pregnant or breast feeding or patients of childbearing
             potential not willing to use a highly effective method of contraception during the
             study and for 3 months following the last dose of study drug;

          -  Male patients whose sexual partner(s) are women of childbearing potential who are not
             willing to use a highly effective method of contraception, one of which includes a
             condom, during the study;

          -  Patients with a history of another primary malignancy that is currently clinically
             significant or currently requires active intervention;

          -  Any concurrent severe and/or uncontrolled medical condition, which could, in the
             opinion of the investigator, compromise participation in the study;

          -  Concurrent participation in another clinical study with an investigational medical
             product.
      
Maximum Eligible Age:65 Years
Minimum Eligible Age:18 Years
Eligible Gender:All
Healthy Volunteers:No

Primary Outcome Measures

Measure:Complete Molecular Response
Time Frame:At week 11 (acceptable window + 1 wk); after completion of two induction courses and before starting of the 1st Consolidation cycle (each induction course is 23 days with continuing ponatinib treatment till the outcome assessing)
Safety Issue:
Description:Percentage of patients with Complete Molecular Response (CMR) after 2 cycles of induction therapy composed by reduced chemotherapy and ponatinib. Minimal Residual Disease (MRD) tested by quantification of BCR-ABL1 transcript using ddPCR method

Secondary Outcome Measures

Measure:CR and CRi
Time Frame:CR and CRi at the end of the 1st Induction Course (Day 23) and at week 11 (acceptable window + 1wk) after completion of the 2nd Induction Course and before starting of the 1st Consolidation Cycle
Safety Issue:
Description:Complete Remission (CR) and Complete Remission with incomplete blood count recovery(CRi)
Measure:PFS
Time Frame:Time from the day of CR/CRi documentation until the date of relapse, or death from any cause whichever came first, assessed up to 36 months
Safety Issue:
Description:Progression Free Survival (PFS)
Measure:OS
Time Frame:Time from the day 1 (starting of the 1st Induction Course) until the date of death from any cause, assessed up to 36 months
Safety Issue:
Description:Overall Survival (OS)
Measure:AlloSCT in the first complete remission
Time Frame:At week 11 (acceptable window + 1 wk); after completion of two induction courses and before starting of the 1st Consolidation cycle (each induction course is 23 days with continuing ponatinib treatment till the outcome assessing)
Safety Issue:
Description:Percentage of patients with suboptimal molecular response after completion of 2 induction course containing ponatinib
Measure:Severity and occurence of adverse events related to ponatinib
Time Frame:During the ponatinib treatment up to 30 days after end of treatment
Safety Issue:
Description:Severity and occurence of adverse events related to ponatinib treatment

Details

Phase:Phase 2
Primary Purpose:Interventional
Overall Status:Not yet recruiting
Lead Sponsor:Institute of Hematology and Blood Transfusion, Czech Republic

Last Updated

September 14, 2020